دورية أكاديمية
أعرض في EDS

Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.

التفاصيل البيبلوغرافية
العنوان: Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.
المؤلفون: Rissardo JP; Neurology Department, Cooper University Hospital, Camden, NJ 08103, USA., Vora NM; Medicine Department, Terna Speciality Hospital and Research Centre, Navi Mumbai 400706, India., Tariq I; Medicine Department, United Medical & Dental College, Karachi 75600, Pakistan., Mujtaba A; Medicine Department, Karachi Medical & Dental College, Karachi 74700, Pakistan., Caprara ALF; Medicine Department, Federal University of Santa Maria, Santa Maria 97105-900, Brazil.
المصدر: Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2023 Nov 13; Vol. 59 (11). Date of Electronic Publication: 2023 Nov 13.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9425208 Publication Model: Electronic Cited Medium: Internet ISSN: 1648-9144 (Electronic) Linking ISSN: 1010660X NLM ISO Abbreviation: Medicina (Kaunas) Subsets: MEDLINE
أسماء مطبوعة: Publication: 2018- : Basel, Switzerland : MDPI
Original Publication: Kaunas : Lietuvos gydytojų sąjunga
مواضيع طبية MeSH: Deep Brain Stimulation*/adverse effects , Deep Brain Stimulation*/methods , Depressive Disorder, Major* , Parkinson Disease*/diagnosis, Humans ; Electrodes, Implanted ; Magnetic Resonance Imaging/adverse effects
مستخلص: In recent decades, deep brain stimulation (DBS) has been extensively studied due to its reversibility and significantly fewer side effects. DBS is mainly a symptomatic therapy, but the stimulation of subcortical areas by DBS is believed to affect the cytoarchitecture of the brain, leading to adaptability and neurogenesis. The neurological disorders most commonly studied with DBS were Parkinson's disease, essential tremor, obsessive-compulsive disorder, and major depressive disorder. The most precise approach to evaluating the location of the leads still relies on the stimulus-induced side effects reported by the patients. Moreover, the adequate voltage and DBS current field could correlate with the patient's symptoms. Implantable pulse generators are the main parts of the DBS, and their main characteristics, such as rechargeable capability, magnetic resonance imaging (MRI) safety, and device size, should always be discussed with patients. The safety of MRI will depend on several parameters: the part of the body where the device is implanted, the part of the body scanned, and the MRI-tesla magnetic field. It is worth mentioning that drug-resistant individuals may have different pathophysiological explanations for their resistance to medications, which could affect the efficacy of DBS therapy. Therefore, this could explain the significant difference in the outcomes of studies with DBS in individuals with drug-resistant neurological conditions.
References: Neurosurgery. 2003 May;52(5):1095-9; discussion 1099-101. (PMID: 12699552)
Neurosurg Focus. 2018 Aug;45(2):E9. (PMID: 30064311)
Front Neurosci. 2018 Sep 03;12:614. (PMID: 30233297)
Parkinsonism Relat Disord. 2016 Mar;24:69-75. (PMID: 26778473)
Lancet. 1991 Feb 16;337(8738):403-6. (PMID: 1671433)
Curr Pain Headache Rep. 2010 Apr;14(2):151-9. (PMID: 20425205)
J Neurosurg. 2011 Aug;115(2):301-9. (PMID: 21495822)
J Neuropsychiatry Clin Neurosci. 2016 Winter;28(1):38-44. (PMID: 26404172)
Neurology. 2000;55(12 Suppl 6):S13-6. (PMID: 11188968)
Front Neurol. 2023 Apr 24;14:1151900. (PMID: 37168666)
Epilepsia Open. 2018 Feb 13;3(1):18-29. (PMID: 29588984)
IEEE Trans Neural Syst Rehabil Eng. 2016 Jun;24(6):710-9. (PMID: 26571534)
Front Hum Neurosci. 2021 Aug 26;15:708481. (PMID: 34512295)
Cureus. 2018 Oct 22;10(10):e3474. (PMID: 30648026)
Prog Brain Res. 2019;249:297-305. (PMID: 31325988)
Nord J Psychiatry. 2016 Oct;70(7):483-91. (PMID: 27103550)
Mol Psychiatry. 2010 Jan;15(1):64-79. (PMID: 18490925)
Neurosurgery. 2006 Feb;58(2):E383; discussion E383. (PMID: 16462466)
Acta Neurochir Suppl. 2007;97(Pt 2):337-42. (PMID: 17691321)
Neurotherapeutics. 2008 Apr;5(2):320-30. (PMID: 18394573)
Neurol Sci. 2021 Jan;42(1):259-266. (PMID: 32638134)
Mov Disord. 2013 Aug;28(9):1292-5. (PMID: 23554137)
Ann Neurol. 2022 Jul;92(1):61-74. (PMID: 35429045)
Nat Rev Neurol. 2021 Feb;17(2):75-87. (PMID: 33244188)
Curr Opin Neurol. 2003 Apr;16(2):165-70. (PMID: 12644744)
Arch Neurol. 1976 Aug;33(8):559-70. (PMID: 821458)
Ann Neurol. 2010 Oct;68(4):521-34. (PMID: 20687206)
NPJ Parkinsons Dis. 2017 Jan 12;3:16024. (PMID: 28725706)
N Engl J Med. 2013 Feb 14;368(7):610-22. (PMID: 23406026)
J Neurosurg. 1967 May;26(5):488-95. (PMID: 5337782)
Lancet Psychiatry. 2017 Nov;4(11):839-849. (PMID: 28988904)
Medicines (Basel). 2023 Aug 21;10(8):. (PMID: 37623813)
Nat Rev Neurol. 2019 Apr;15(4):234-242. (PMID: 30778210)
PLoS One. 2017 Jul 5;12(7):e0178984. (PMID: 28678830)
Front Psychiatry. 2019 May 10;10:319. (PMID: 31133898)
Mov Disord. 2009 Oct 15;24(13):2020-2. (PMID: 19672983)
Brain Stimul. 2019 Jan - Feb;12(1):175-183. (PMID: 30245163)
Mov Disord. 2011 Jul;26(8):1398-406. (PMID: 21714001)
Brain Stimul. 2016 Mar-Apr;9(2):296-304. (PMID: 26827109)
Neuroscientist. 2016 Jun;22(3):313-22. (PMID: 25888630)
Nat Rev Neurol. 2019 Mar;15(3):148-160. (PMID: 30683913)
Curr Behav Neurosci Rep. 2015;2(2):41-48. (PMID: 26317062)
Mov Disord. 2020 Apr;35(4):555-561. (PMID: 32039501)
World Neurosurg. 2013 Sep-Oct;80(3-4):S29.e11-4. (PMID: 22743202)
Br J Neurosurg. 2021 Feb;35(1):57-64. (PMID: 32476485)
Mov Disord Clin Pract. 2017 Aug 12;4(4):486-494. (PMID: 30363085)
Parkinsons Dis. 2017;2017:9360354. (PMID: 28848685)
Lancet Neurol. 2013 Jan;12(1):37-44. (PMID: 23168021)
Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):105-115. (PMID: 35976323)
Ther Adv Psychopharmacol. 2018 Feb;8(2):73-92. (PMID: 29399320)
Horm Behav. 2003 Sep;44(3):171-7. (PMID: 14609539)
JAMA Neurol. 2014 Oct;71(10):1290-5. (PMID: 25155481)
Neurol Neurochir Pol. 2016;50(3):207-10. (PMID: 27154450)
Neuroscience. 2010 Sep 15;169(4):1768-78. (PMID: 20541595)
Mol Psychiatry. 2015 Mar;20(3):353-60. (PMID: 24798585)
Front Aging Neurosci. 2022 Apr 07;14:819730. (PMID: 35462695)
Mov Disord Clin Pract. 2023 Mar 31;10(5):783-793. (PMID: 37205250)
J Alzheimers Dis. 2018;62(2):621-633. (PMID: 29400666)
Epilepsy Behav. 2020 Apr;105:106969. (PMID: 32113113)
N Engl J Med. 2010 Jun 3;362(22):2077-91. (PMID: 20519680)
Mov Disord. 2006 Jun;21 Suppl 14:S305-27. (PMID: 16810676)
PLoS One. 2014 Dec 03;9(12):e114140. (PMID: 25469706)
Neurology. 2005 Jun 28;64(12):2008-20. (PMID: 15972843)
Pharmacol Rev. 2018 Apr;70(2):197-245. (PMID: 29487083)
Neurotherapeutics. 2020 Oct;17(4):1525-1538. (PMID: 33118132)
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:148-160. (PMID: 30641094)
Am J Ophthalmol Case Rep. 2022 Apr 16;26:101531. (PMID: 35509285)
Front Hum Neurosci. 2020 Mar 27;14:54. (PMID: 32292333)
Ann Neurol. 2013 May;73(5):565-75. (PMID: 23483564)
Neurology. 1998 May;50(5):1323-6. (PMID: 9595981)
Mov Disord. 1998;13 Suppl 3:119-25. (PMID: 9827607)
Mov Disord. 2012 Mar;27(3):357-63. (PMID: 21997283)
Brain. 2020 Dec 5;143(11):3393-3407. (PMID: 33150359)
Neurosurg Focus. 2015 Jun;38(6):E4. (PMID: 26030704)
Front Hum Neurosci. 2021 Nov 26;15:757579. (PMID: 34899219)
Ther Adv Neurol Disord. 2009 Nov;2(6):20-8. (PMID: 21180627)
J Neurol Neurosurg Psychiatry. 2006 Jul;77(7):868-72. (PMID: 16574733)
Neurosurg Focus. 2018 Aug;45(2):E4. (PMID: 30064326)
Front Syst Neurosci. 2017 Dec 20;11:94. (PMID: 29375329)
Arch Neurol. 2011 Dec;68(12):1550-6. (PMID: 21825213)
Neuropsychiatr Dis Treat. 2019 Apr 29;15:1061-1075. (PMID: 31114210)
Surg Neurol Int. 2011;2:131. (PMID: 22059126)
N Engl J Med. 2006 Aug 31;355(9):896-908. (PMID: 16943402)
N Am J Med Sci. 2014 Aug;6(8):359-69. (PMID: 25210668)
Mov Disord Clin Pract. 2018 Feb 28;5(3):246-254. (PMID: 30363375)
J Neurophysiol. 2016 Jan 1;115(1):19-38. (PMID: 26510756)
Mol Psychiatry. 2018 Apr;23(4):843-849. (PMID: 28397839)
Alzheimers Dement. 2014 Sep;10(5):571-81. (PMID: 24411134)
Otolaryngol Head Neck Surg. 2009 Aug;141(2):285-7. (PMID: 19643267)
Neurosurgery. 2013 Feb;72(2):221-30; discussion 231. (PMID: 23149975)
Front Neurosci. 2021 Jun 14;15:680938. (PMID: 34194295)
Eur J Neurol. 2012 Jan;19(1):121-7. (PMID: 21668586)
J Clin Neurosci. 2005 Jun;12(5):515-9. (PMID: 15993077)
Front Hum Neurosci. 2022 May 16;16:806513. (PMID: 35652005)
Ann Neurol. 2000 Apr;47(4 Suppl 1):S141-6. (PMID: 10762141)
Ann N Y Acad Sci. 2013 Apr;1282:119-28. (PMID: 23227826)
Sleep Med. 2020 Dec;76:155-157. (PMID: 33217666)
J Magn Reson Imaging. 2019 Jun;49(6):1736-1749. (PMID: 30552842)
Neuropharmacology. 2004;47 Suppl 1:227-41. (PMID: 15464140)
Neurosurgery. 2020 Feb 1;86(2):191-202. (PMID: 30799493)
Acta Neuropathol. 1983;61(2):101-8. (PMID: 6637393)
Surg Neurol. 1998 Feb;49(2):145-53; discussion 153-4. (PMID: 9457264)
Front Aging Neurosci. 2022 Jul 08;14:874692. (PMID: 35875799)
Neurol Sci. 2012 Dec;33(6):1285-303. (PMID: 22271259)
J Alzheimers Dis. 2016 Sep 6;54(2):777-87. (PMID: 27567810)
JAMA Psychiatry. 2016 May 1;73(5):456-64. (PMID: 27049915)
Clin Neurol Neurosurg. 2017 Jul;158:103-107. (PMID: 28505539)
Chin Med J (Engl). 2015 May 5;128(9):1190-5. (PMID: 25947402)
Medicine (Baltimore). 2018 Aug;97(35):e12153. (PMID: 30170458)
Brain Sci. 2018 Jan 20;8(1):. (PMID: 29361705)
Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 2):2676-88. (PMID: 24035740)
JAMA. 2009 Jan 7;301(1):63-73. (PMID: 19126811)
Neurologist. 2011 Sep;17(5):263-8. (PMID: 21881468)
Lancet. 1997 Dec 6;350(9092):1675. (PMID: 9400514)
J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):474-482. (PMID: 30337440)
J Neurol. 2003 Feb;250 Suppl 1:I47-52. (PMID: 12761637)
J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):410-2. (PMID: 16484657)
Acta Neuropsychiatr. 2020 Apr;32(2):57-64. (PMID: 31452489)
J Neurosurg. 2016 Apr;124(4):908-16. (PMID: 26495947)
Clin Neurophysiol. 2004 Nov;115(11):2542-57. (PMID: 15465444)
Mol Psychiatry. 2018 May;23(5):1094-1112. (PMID: 29483673)
Front Psychiatry. 2017 Mar 20;8:44. (PMID: 28373849)
J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):613-616. (PMID: 28214797)
J Neurol Sci. 2011 Nov 15;310(1-2):267-70. (PMID: 21764406)
Eur Eat Disord Rev. 2008 Sep;16(5):355-60. (PMID: 18711713)
Neurology. 2018 Sep 11;91(11):e1013-e1021. (PMID: 30111549)
Neurology. 2017 Nov 14;89(20):2083-2091. (PMID: 29030455)
Surg Neurol Int. 2012;3(Suppl 4):S290-311. (PMID: 23230534)
J Neurosurg. 2019 Aug 1;131(2):333-342. (PMID: 31370011)
Biol Psychiatry. 2009 Feb 15;65(4):e5-6. (PMID: 19006786)
J Neurosurg. 2013 Jul;119(1):56-63. (PMID: 23560573)
Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S118-22. (PMID: 24262161)
Neuromolecular Med. 2010 Mar;12(1):27-43. (PMID: 20069392)
Neurology. 2000 Aug 8;55(3):411-8. (PMID: 10932277)
Obes Surg. 2020 Oct;30(10):4145-4148. (PMID: 32451916)
Epilepsia. 2010 May;51(5):899-908. (PMID: 20331461)
World Neurosurg. 2013 Sep-Oct;80(3-4):S31.e1-8. (PMID: 22469523)
فهرسة مساهمة: Keywords: DBS; IPG; Parkinson’s disease; brain stimulation; electrical stimulation; movement disorder; neurology; neurosurgery; symptomatic; tremor
تواريخ الأحداث: Date Created: 20231125 Date Completed: 20231127 Latest Revision: 20231127
رمز التحديث: 20231128
مُعرف محوري في PubMed: PMC10673515
DOI: 10.3390/medicina59111991
PMID: 38004040
قاعدة البيانات: MEDLINE
الوصف
تدمد:1648-9144
DOI:10.3390/medicina59111991